New Medicine - A Comprehensive Information and Consulting Service  
HOME PRODUCTS & SERVICES ORDER/INQUIRY PRESS RELEASES EMPLOYMENT CONTACT US

Volume 1, # 9 - January, 1996

Table of Contents

STATE-OF-THE-ART MANAGEMENT OF CANCER
LEUKEMIA AND MYELOPROLIFERATIVE/MYELODYSPLASTIC DISORDERS
Epidemiology, Etiology and Classification 202
  Acute leukemia 202
    Acute myelogenous leukemia (AML) 202
    Acute lymphoblastic leukemia (ALL) 202
    Adult T cell leukemia (ATL) 203
  Chronic leukemia 203
    Chronic myelogenous leukemia (CML) 203
    Chronic lympocytic leukemia (ALL) 204
    Hairy cell leukemia (HCL) 204
  Myeloproliferative Disorders 204
  Myelodisyplastic Syndromes (MDS) 204
Pathogenesis and Genetic Abnormalities 204
  Acute leukemia 204
  Chronic leukemia 205
  Myeloproliferative Disorders 206
  Myelodysplastic Syndromes (MDS) 206
Presentation and Diagnosis 206
  Acute Leukemia 206
  Chronic Leukemia 206
    Oncor 206
  Myeloproliferative Disorders 206
  Myelodysplastic Syndromes 207
Prognosis 207
  Acute Leukemia 207
  Chronic Leukemia 208
  Myeloproliferative Disorders 208
  Myelodysplastic Syndromes 209
Treatment Options for Myeloproliferative and Myelodysplastic Disorders 209
  Myeloproliferative Disorders 209
  Myelodysplastic Syndromes 209
Current Treatment Options in Acute and Chronic Leukemias 209
  Chemotherapy in Acute Leukemia 210
    AML 210
      All-trans retinoid acid 211
    ALL 211
      Pegaspargase 211
    ATL 212
  Chemotherapy in Chronic Leukemia 212
    CML 212
      Roferon-A 212
    CLL 213
      Fludarabine 213
      Immunoglobulin 214
    HCL 214
      Pentostatin 214
      Cladribine 214
      Recombinant IFN-a 214
  Bone Marrow Transplantation in Acute Leukemia 214
  Bone Marrow Transplantation in Chronic Leukemia 215
  Growth Factors 215
MEETING COVERAGE
18TH ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
San Antonio, TX - December 10-13, 1995
ADVANCES IN THE MANAGEMENT OF BREAST CANCER
New Imaging Approaches in Breast Cancer 216
  Magnetic Resonance Imaging 216
  Positron Emission Tomography 216
Hormonal Therapy 216
  Tamoxifen (Nolvadex: Zeneca) 216
  Anastrozole (Armidex: Zeneca) 216
  ICI 182.780 (Zeneca) 217
  Liarozole (Liazozole) Fumarate (R85246, Janssen Research Foundation) 217
  Leuprorelin Sustained Release (TAP-144SR, TAP Pharmaceuticals) 217
Chemotherapy 217
  Taxanes 217
    Docetaxel 218
    Paclitaxel 218
  Vinorelbine (Navelbine, Glaxo Wellcome) 219
  High Dose Chemotherapy 219

HOME | PRODUCTS & SERVICES | ORDER/INQUIRY | PRESS RELEASES | EMPLOYMENT | CONTACT US

NEW MEDICINE, INC.
PHONE: 949-830-0448   FAX: 949-830-0887